vs

Side-by-side financial comparison of Doximity, Inc. (DOCS) and Harmony Biosciences Holdings, Inc. (HRMY). Click either name above to swap in a different company.

Harmony Biosciences Holdings, Inc. is the larger business by last-quarter revenue ($243.8M vs $185.1M, roughly 1.3× Doximity, Inc.). Doximity, Inc. runs the higher net margin — 33.3% vs 9.2%, a 24.0% gap on every dollar of revenue. On growth, Harmony Biosciences Holdings, Inc. posted the faster year-over-year revenue change (21.1% vs 9.8%). Over the past eight quarters, Harmony Biosciences Holdings, Inc.'s revenue compounded faster (25.6% CAGR vs 25.2%).

Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.

Harmony Biosciences Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare neurological and central nervous system disorders. Its primary market is the United States, with its core product serving patients living with narcolepsy and other sleep-related CNS conditions across adult and pediatric segments.

DOCS vs HRMY — Head-to-Head

Bigger by revenue
HRMY
HRMY
1.3× larger
HRMY
$243.8M
$185.1M
DOCS
Growing faster (revenue YoY)
HRMY
HRMY
+11.4% gap
HRMY
21.1%
9.8%
DOCS
Higher net margin
DOCS
DOCS
24.0% more per $
DOCS
33.3%
9.2%
HRMY
Faster 2-yr revenue CAGR
HRMY
HRMY
Annualised
HRMY
25.6%
25.2%
DOCS

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
DOCS
DOCS
HRMY
HRMY
Revenue
$185.1M
$243.8M
Net Profit
$61.6M
$22.5M
Gross Margin
89.9%
71.9%
Operating Margin
38.9%
15.8%
Net Margin
33.3%
9.2%
Revenue YoY
9.8%
21.1%
Net Profit YoY
-18.1%
-54.6%
EPS (diluted)
$0.31
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DOCS
DOCS
HRMY
HRMY
Q4 25
$185.1M
$243.8M
Q3 25
$168.5M
$239.5M
Q2 25
$145.9M
$200.5M
Q1 25
$138.3M
$184.7M
Q4 24
$168.6M
$201.3M
Q3 24
$136.8M
$186.0M
Q2 24
$126.7M
$172.8M
Q1 24
$118.1M
$154.6M
Net Profit
DOCS
DOCS
HRMY
HRMY
Q4 25
$61.6M
$22.5M
Q3 25
$62.1M
$50.9M
Q2 25
$53.3M
$39.8M
Q1 25
$62.5M
$45.6M
Q4 24
$75.2M
$49.5M
Q3 24
$44.2M
$46.1M
Q2 24
$41.4M
$11.6M
Q1 24
$40.6M
$38.3M
Gross Margin
DOCS
DOCS
HRMY
HRMY
Q4 25
89.9%
71.9%
Q3 25
90.3%
75.1%
Q2 25
89.2%
81.0%
Q1 25
89.5%
82.7%
Q4 24
91.6%
73.0%
Q3 24
90.0%
77.0%
Q2 24
89.3%
81.4%
Q1 24
89.4%
82.2%
Operating Margin
DOCS
DOCS
HRMY
HRMY
Q4 25
38.9%
15.8%
Q3 25
37.8%
27.3%
Q2 25
37.4%
24.0%
Q1 25
35.2%
30.4%
Q4 24
47.4%
27.7%
Q3 24
38.8%
33.2%
Q2 24
36.4%
12.4%
Q1 24
35.5%
33.7%
Net Margin
DOCS
DOCS
HRMY
HRMY
Q4 25
33.3%
9.2%
Q3 25
36.8%
21.2%
Q2 25
36.5%
19.8%
Q1 25
45.2%
24.7%
Q4 24
44.6%
24.6%
Q3 24
32.3%
24.8%
Q2 24
32.7%
6.7%
Q1 24
34.4%
24.8%
EPS (diluted)
DOCS
DOCS
HRMY
HRMY
Q4 25
$0.31
$0.38
Q3 25
$0.31
$0.87
Q2 25
$0.27
$0.68
Q1 25
$0.31
$0.78
Q4 24
$0.37
$0.85
Q3 24
$0.22
$0.79
Q2 24
$0.21
$0.20
Q1 24
$0.20
$0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DOCS
DOCS
HRMY
HRMY
Cash + ST InvestmentsLiquidity on hand
$64.8M
$775.3M
Total DebtLower is stronger
$163.7M
Stockholders' EquityBook value
$979.3M
$870.2M
Total Assets
$1.2B
$1.3B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DOCS
DOCS
HRMY
HRMY
Q4 25
$64.8M
$775.3M
Q3 25
$169.2M
$672.6M
Q2 25
$137.3M
$565.3M
Q1 25
$209.6M
$507.0M
Q4 24
$165.3M
$467.2M
Q3 24
$184.2M
$410.5M
Q2 24
$111.4M
$346.9M
Q1 24
$96.8M
$372.4M
Total Debt
DOCS
DOCS
HRMY
HRMY
Q4 25
$163.7M
Q3 25
$168.5M
Q2 25
$172.1M
Q1 25
$175.7M
Q4 24
$179.3M
Q3 24
$182.8M
Q2 24
$186.4M
Q1 24
$190.0M
Stockholders' Equity
DOCS
DOCS
HRMY
HRMY
Q4 25
$979.3M
$870.2M
Q3 25
$1.1B
$835.1M
Q2 25
$1.0B
$773.1M
Q1 25
$1.1B
$720.5M
Q4 24
$1.0B
$659.2M
Q3 24
$961.2M
$596.8M
Q2 24
$913.6M
$538.6M
Q1 24
$901.4M
$515.4M
Total Assets
DOCS
DOCS
HRMY
HRMY
Q4 25
$1.2B
$1.3B
Q3 25
$1.3B
$1.2B
Q2 25
$1.2B
$1.1B
Q1 25
$1.3B
$1.1B
Q4 24
$1.2B
$999.2M
Q3 24
$1.1B
$928.1M
Q2 24
$1.1B
$858.4M
Q1 24
$1.1B
$847.0M
Debt / Equity
DOCS
DOCS
HRMY
HRMY
Q4 25
0.19×
Q3 25
0.20×
Q2 25
0.22×
Q1 25
0.24×
Q4 24
0.27×
Q3 24
0.31×
Q2 24
0.35×
Q1 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DOCS
DOCS
HRMY
HRMY
Operating Cash FlowLast quarter
$60.9M
$126.2M
Free Cash FlowOCF − Capex
$126.0M
FCF MarginFCF / Revenue
51.7%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
0.99×
5.61×
TTM Free Cash FlowTrailing 4 quarters
$347.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DOCS
DOCS
HRMY
HRMY
Q4 25
$60.9M
$126.2M
Q3 25
$93.9M
$108.7M
Q2 25
$62.1M
$79.3M
Q1 25
$98.5M
$34.0M
Q4 24
$65.2M
$75.6M
Q3 24
$68.3M
$70.5M
Q2 24
$41.2M
$42.6M
Q1 24
$63.9M
$31.1M
Free Cash Flow
DOCS
DOCS
HRMY
HRMY
Q4 25
$126.0M
Q3 25
$108.7M
Q2 25
$79.3M
Q1 25
$33.9M
Q4 24
$75.0M
Q3 24
$70.5M
Q2 24
$42.0M
Q1 24
$31.1M
FCF Margin
DOCS
DOCS
HRMY
HRMY
Q4 25
51.7%
Q3 25
45.4%
Q2 25
39.6%
Q1 25
18.3%
Q4 24
37.3%
Q3 24
37.9%
Q2 24
24.3%
Q1 24
20.1%
Capex Intensity
DOCS
DOCS
HRMY
HRMY
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.0%
0.1%
Q4 24
0.0%
0.3%
Q3 24
0.0%
0.0%
Q2 24
0.0%
0.4%
Q1 24
0.0%
0.0%
Cash Conversion
DOCS
DOCS
HRMY
HRMY
Q4 25
0.99×
5.61×
Q3 25
1.51×
2.14×
Q2 25
1.16×
1.99×
Q1 25
1.58×
0.75×
Q4 24
0.87×
1.53×
Q3 24
1.55×
1.53×
Q2 24
1.00×
3.68×
Q1 24
1.57×
0.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DOCS
DOCS

Subscription$175.4M95%
Service Other$9.7M5%

HRMY
HRMY

Segment breakdown not available.

Related Comparisons